2. Apoptosis Anti-infection
  3. Apoptosis Parasite
  4. RRx-001

RRx-001 

Cat. No.: HY-16438 Purity: 99.16%
COA Handling Instructions

RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity. RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α. RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity.

For research use only. We do not sell to patients.

RRx-001 Chemical Structure

RRx-001 Chemical Structure

CAS No. : 925206-65-1

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solution
10 mM * 1 mL in DMSO USD 158 In-stock
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
 USD 158 In-stock
Solid
5 mg USD 144 In-stock
10 mg USD 190 In-stock
50 mg USD 620 In-stock
100 mg USD 990 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

RRx-001 Related Antibodies

Top Publications Citing Use of Products

    RRx-001 purchased from MCE. Usage Cited in: J Virol. 2023 Feb 16;e0001623.  [Abstract]

    RRx-001 (2.5, 5, 10, 20, 100 µM; 12 h) significantly and dose-dependently reduces Newcastle disease virus (NDV) NP protein expression in NDV-infected cells.

    RRx-001 purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2019 Feb 20;38(1):90.  [Abstract]

    Whole cell lysates from J82 shCCDC6 or shCTRL cells, treated with different concentrations of RRx-001, or untreated, are immunoblotted with anti-CCDC6 antibody. γH2AX levels are shown. Tubulin is used as loading control.

    RRx-001 purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2019 Feb 20;38(1):90.  [Abstract]

    Protein levels of DNMT1 and CCDC6 in J82 cells treated with different concentrations of RRx-001, as determined by western blot. Vinculin and Tubulin are used as internal controls for sample loading. 5-AZA is used as positive control for inhibition of DNMT1 expression.

    View All Parasite Isoform Specific Products:

    View All Isoforms
    Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity[1]. RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α[2]. RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity[3].

    IC50 & Target

    Plasmodium

     

    In Vitro

    RRx-001 (0-5 μM, 24 hours) inhibits MM cells growth and overcomes resistance to novel and conventional therapies[1].
    RRx-001 blocks migration of MM cells and associated angiogenesis[1].
    RRx-001 induces significant G1 phase growth arrest, with a concomitant decrease in the S phase. RRx-001 triggers significant apoptosis in MM cells[1].
    RRx-001 inhibits DNA methylation by downregulating DNA methytransferases[1].
    RRx-001 and the supernatant of RRx-001-treated macrophages downregulates CD47 on tumor cells and SIRPα on macrophages[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    RRx-001 Related Antibodies

    Cell Viability Assay[1]

    Cell Line: Human MM-cell lines (MM.1S, RPMI-8226, H929, ARP1, KMS-11, OPM2, LR5, ANBL6.WT), along with drug resistant cell lines such as (MM.1R, Dox40, LR5, ANBL6.BR, RPMI-8226).
    Concentration: 0-5 μM.
    Incubation Time: 24 hours.
    Result: Induced a dose-dependent significant (p < 0.05) decrease in viability of all cell lines.
    In Vivo

    RRx-001 (5 mg/kg or 10 mg/kg, I.V., thrice-weekly for 24 days) inhibits tumor growth and prolongs survival in a xenograft mouse model[1].
    RRx-001 (10 mg/kg, IP, twice a week and once a day) exhibits potent anti-cancer activity on the A549 lung cancer model dependent on the presence of tumor-associated macrophages (TAMs) in tumor tissue[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: CB-17 SCID-mice were subcutaneously inoculated with 5.0 × 106 MM.1S cells in 100 µL of serum-free RPMI 1640 medium[1].
    Dosage: 5 mg/kg or 10 mg/kg.
    Administration: I.V., thrice-weekly for 24 days.
    Result: Blocked MM tumor growth and enhances survival.
    Treatment was well tolerated, suggested by no apparent weight loss.
    Animal Model: Female BALB/c nude mice (19.2 ± 1.7 g) based on A549 lung cancer model[2].
    Dosage: 10 mg/kg.
    Administration: IP, twice a week and once a day.
    Result: Resulted in the most significant tumor growth retardation.
    Reduction of resident macrophages in tumor-bearing mice attenuates the antitumor activity of RRx-001.
    Clinical Trial
    Molecular Weight

    268.02

    Appearance

    Solid

    Formula

    C5H6BrN3O5
    CAS No.
    SMILES

    BrCC(N1CC([N+]([O-])=O)([N+]([O-])=O)C1)=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 100 mg/mL (373.11 mM)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.7311 mL 18.6553 mL 37.3107 mL
    5 mM 0.7462 mL 3.7311 mL 7.4621 mL
    10 mM 0.3731 mL 1.8655 mL 3.7311 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.5 mg/mL (9.33 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 2.5 mg/mL (9.33 mM); Clear solution

    • 3.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.5 mg/mL (9.33 mM); Clear solution

    *All of the co-solvents are available by MCE.
    Purity & Documentation
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    RRx-001 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Keywords:

    RRx-001925206-65-1RRx001RRx 001ApoptosisParasiteInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email address *

    Phone number *

    		 

    Organization name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    RRx-001
    Cat. No.:
    HY-16438
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email address *

    Phone number

    		 

    Department *

    Organization name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.